INTRODUCTION: Although treatment options for men with metastatic castrate-resistant prostate cancer have improved in recent years, the outlook for patients remains poor, with overall survival in the region of 2 years.
Response rates with chemotherapy are modest and disease progression is usually observed within months of stopping treatment.
CASE PRESENTATION: We present a case of a 72-year-old White man of British origin with metastatic castrate-resistant prostate cancer with bulky lymphadenopathy and a serum prostate-specific antigen of 295μg/L. He received treatment with docetaxel chemotherapy plus prednisolone, but received just 3 cycles before treatment was stopped due to toxicity and lack of response (prostate-specific antigen was 276μg/L 4 weeks after the last dose and there was a confirmed stable appearance on computed tomography scan). Unexpectedly, at follow-up 4 months later, the patient was clinically better; his prostate-specific antigen had dramatically improved to 4.1μg/L and a re-staging computed tomography scan revealed complete resolution of his bulky lymphadenopathy. At the time, he was receiving a luteinising hormone-releasing hormone analogue but no other disease-modulating treatment. He remains well and asymptomatic, with his most recent serum prostate-specific antigen measuring 0.14μg/L, 18 months after last receiving chemotherapy.
CONCLUSION: We report a case of complete and durable regression of metastatic castrate-resistant prostate cancer following palliative chemotherapy which, to the best of our knowledge, has not previously been reported in the literature.
Written by:
Daverede L, Ralph C, Jagdev SP, Trigonis I, Trainor S, Harnden P, Weston M, Paul A, Vasudev NS. Are you the author?
Department of Medical Oncology, St James's Institute of Oncology, Leeds LS9 7TF, UK.
Reference: J Med Case Rep. 2014 Apr 9;8(1):122.
doi: 10.1186/1752-1947-8-122
PubMed Abstract
PMID: 24717107
UroToday.com mCRPC Treatment Section
